E De Cock - Concepedia

Author

E De Cock

United BioSource Corporation (United Kingdom)ORCID

Also Known As

E De Cock, E de Cock, E. De Cock, E. De cock, ERWIN DE COCK, Erwin DE COCK, Erwin De Cock

Publications

741

Citations

H-Index

Concepts

All Affiliations

United BioSource Corporation (United Kingdom)Université Libre de Bruxelles La Roche College Roche (Switzerland)Pfizer (United States)

About

E De Cock is an author at United BioSource Corporation (United Kingdom) specializing in medicine, pharmacotherapy, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	233
2	Health Sciences	1	1	44
3	Public Health	1	1	17
4	Social Sciences	1	1	27
5	Emergency Medicine	1	1	10

E De Cock

Publications

608

Citations

H-Index

Page 1

	Year	Citations
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with <scp>HER</scp>2‐positive early breast cancer E De Cock, Xavier Pivot, Nik Hauser, Cancer Medicine	2016	102
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries E De Cock, Persefoni Kritikou, Mariana Sandoval, PLoS ONE	2016	100
Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany E De Cock, Wolfgang A. Krueger, S. Sorensen, Infection Health SciencesAntimicrobial StewardshipAntibioticsHealthcare-associated InfectionSuspected Methicillin-resistant Staphylococcus	2009	44
Costs of managing anemia with erythropoiesis‐stimulating agents during hemodialysis: A time and motion study Brigitte Schiller, Sheila Doss, E De Cock, Hemodialysis International	2008	35
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy E De Cock, John Hutton, Peter Canney, Supportive Care in Cancer Bone DiseaseBone HealthOncologyGeneric PamidronateBreast Cancer Patients	2005	34
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom E De Cock, John Hutton, Peter Canney, Clinical Therapeutics Breast OncologyMedicineCancer ManagementBreast CancerUnited Kingdom	2005	31
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland☆ Ágnes Benedict, Jorge Arellano, E De Cock, Journal of Affective Disorders PsychiatryPsychotropic MedicationPharmacologyDepressionPsychopharmacology	2009	27
Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany Dirk Schürmann, Sonja Sorensen, E De Cock, The European Journal of Health Economics Hospital MedicineAntibioticsAntibiotic AdjuvantHealthcare-associated InfectionPatient Safety	2008	27
Hepatitis B Management Costs in France, Italy, Spain, and the United Kingdom Ruth E. Brown, E De Cock, Xavier Colin, Journal of Clinical Gastroenterology	2004	25
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study Saartje Van de Vondel, Filip Baert, C Reenaers, Inflammatory Bowel Diseases	2018	25

Page 1